Technical Analysis for STIM - Neuronetics, Inc.

Grade Last Price % Change Price Change
grade F 4.16 -7.76% -0.35
STIM closed down 7.76 percent on Monday, November 18, 2019, on 1.36 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Dec 1

*** please verify all earnings dates ***
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical STIM trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Outside Day Range Expansion -7.76%
Wide Bands Range Expansion -7.76%
Oversold Stochastic Weakness -7.76%
Narrow Range Bar Range Contraction -9.37%
NR7 Range Contraction -9.37%
Inside Day Range Contraction -9.37%

Older signals for STIM ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
STIM Chart by TradingView
Basic chart:
Profile
Neuronetics Inc is a commercial stage medical technology company. It is focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders.
Health Psychiatry Neurotechnology Corcept Therapeutics Treatment Of Depression Stage Medical Technology
Is STIM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Nov 12 The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
Nov 9 Neuronetics, Inc. (STIM) CEO Chris Thatcher on Q3 2019 Results - Earnings Call Transcript
Nov 7 Neuronetics® to Present New Depression Research at 15th Annual Neuroscience Education Institute Congress
Nov 5 Midday Gainers / Losers
Nov 5 ImmunoGen among healthcare gainers; Curis and CHF Solutions among losers
Nov 5 Neuronetics down 28% on guidance cut
Nov 5 Neuronetics (STIM) Reports Q3 Loss, Lags Revenue Estimates
Nov 5 Neuronetics EPS beats by $0.05, misses on revenue
Nov 5 Neuronetics Reports Third Quarter 2019 Financial and Operating Results
Nov 1 Neuronetics® Announces Appointment of Sheryl Conley to its Board of Directors
See more STIM news...
Indicators
Indicator Value
52 Week High 21.25
52 Week Low 4.0
Average Volume 103,962
200-Day Moving Average 12.4553
50-Day Moving Average 8.4612
20-Day Moving Average 6.83
10-Day Moving Average 4.762
Average True Range 0.4866
ADX 46.41
+DI 7.2325
-DI 51.0608
Chandelier Exit (Long, 3 ATRs ) 7.930200000000001
Chandelier Exit (Short, 3 ATRs ) 5.4598
Upper Bollinger Band 10.998
Lower Bollinger Band 2.662
Percent B (%b) 0.18
BandWidth 122.04978
MACD Line -1.2987
MACD Signal Line -1.0589
MACD Histogram -0.2399
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.03
Resistance 3 (R3) 5.07 4.83 4.89
Resistance 2 (R2) 4.83 4.61 4.81 4.84
Resistance 1 (R1) 4.49 4.47 4.37 4.45 4.79
Pivot Point 4.25 4.25 4.19 4.23 4.25
Support 1 (S1) 3.91 4.03 3.79 3.87 3.53
Support 2 (S2) 3.67 3.89 3.65 3.48
Support 3 (S3) 3.33 3.67 3.44
Support 4 (S4) 3.29